TLC 6740
Alternative Names: TLC-6740Latest Information Update: 26 Jun 2024
At a glance
- Originator Gilead Sciences
- Developer OrsoBio
- Class Antihypercalcaemics; Hepatoprotectants; Obesity therapies
- Mechanism of Action Mitochondrial oxidative phosphorylation uncouplers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Diabetes mellitus; Lipodystrophy; Non-alcoholic steatohepatitis; Obesity